WE OPERATE THROUGH FOLLOWING BUSINESS MODEL
-
Technology & CDMOPresently we have 3 strategic partnership companies: 1 R&D center (about 30 R&D staff), 2 manufacturing sites. Both sites passed audit for advanced intermediates and APIs from authorities like PMDA, SFDA; they also both passed frequent EHS & Quality audit from big pharma like Pfizer, Norvatis,Astellas, Daiichi Sankyo, etc -
International Marketing Service-Business RepresentativeSourcing of API、Intermediates and KSM for advanced / regulated market.This is TW’S traditional business. Our founder team has been studious in the industry for over a decade, It has successfully explored international markets such as Japan,India, South Korea and Europe. We have a high reputation and abundant market experiences. We have closely collaboration with worldwide pharmaceutical companies. Currently we have channelized our platform of stable business with the TOP 200 Indian pharmaceutical companies, and have long-term cooperation with the world's top 50 pharmaceutical companies, we’re still working on continuing to strengthen our relationship. -
API Import RegistrationWe collaborate with our strategic partner for API Import Registration and marketing activity.
We can provide suppliers with a simple, and hassle free process through which they can do the registration in India and China. We adhere to strict confidentiality norms, and look to make the process quick, and smooth for the producer. -
International Marketing Service-Business RepresentativeSourcing of API、Intermediates and KSM for advanced / regulated market.This is TW’S traditional business. Our founder team has been studious in the industry for over a decade, It has successfully explored international markets such as Japan,India, South Korea and Europe. We have a high reputation and abundant market experiences. We have closely collaboration with worldwide pharmaceutical companies. Currently we have channelized our platform of stable business with the TOP 200 Indian pharmaceutical companies, and have long-term cooperation with the world's top 50 pharmaceutical companies, we’re still working on continuing to strengthen our relationship.
Copyright © 2025 Sinofuture Pharma
粤20250816100586